Abstract
Stenotrophomonas maltophilia (Sm) plays an important role as an opportunistic pathogen in immunocompromised individuals. The growing detection rates of this bacterium in hospitalized patients are associated with the invasiveness of therapeutic and diagnostic procedures and the selection pressure of antibiotic therapy. A broad range of infections that can be caused by Sm is frequently bound to biofilm. The high level of intrinsic resistance to many unrelated antibiotics and increasing acquired resistance to the drug of choice, trimethoprim-sulfamethoxazole pose a threat for the near future when our treatment options may become depleted. Prevention of colonization and infection consists in consequent implementation of the rules governing nosocomial infection control, rational use of antibiotics including the optimization of selection and testing of antimicrobial agents suitable for the treatment of stenotrophomonad infections.
Article PDF
Similar content being viewed by others
Abbreviations
- AAC:
-
aminoglycoside acetyltransferase
- APH:
-
aminoglycoside phosphotransferase
- DSF:
-
diffusible signaling factor
- ESBL:
-
extended spectrum β-lactamase
- IL:
-
interleukin
- MIC:
-
minimum inhibitory concentration
- PFGE:
-
pulsed field gel electrophoresis
- Sm :
-
Stenotrophomonas maltophilia
- TMP-SMX:
-
trimethoprim-sulfamethoxazole
- TNF:
-
tumor necrosis factor
- BSAC:
-
British Society for Antimicrobial Chemotherapy
- CLSI:
-
Clinical Laboratory Standards Institute
- EUCAST:
-
European Committee on Antimicrobial Susceptiblity Testing
References
Al-Jasser A.M.: Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann.Clin.Microbiol. Antimicrob.18, 5–23 (2006).
Alonzo A., Martinez J.L.: Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob.Agents Chemother.45, 1879–1881 (2001).
Anderson S.W., Stapp J.R., Burns J.L., Xuan Q.: Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis. J.Clin.Microbiol.45, 529–535 (2007).
Andrews J.M.: BSAC standardized disc susceptibility testing method (version 7). J.Antimicrob.Chemother.62, 256–278 (2008).
Avison M.B., Higgins C.S., Ford P.J., von Heldreich C.J., Bennet P.M.: Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia. J.Antimicrob.Chemother.49, 387–389 (2002).
Avison M.B., Von Heldreich C.J., Higgins C.S., Bennett P.M., Walsh T.R.: A TEM-2β-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J.Antimicrob.Chemother.46, 879–884 (2000).
Barchittaa M., Cipresso A.R., Giaquintad L., Romeod M.A., Denarod C., Pennisic C., Agodi A.: Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Internat.J.Hyg.Environ.Health212, 330–337 (2009).
Bin Abdulhak A.A., Zimmerman V., Bassim T., Beirouti A., Baddour L.M., Tleyjeh I.M.: Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature. Diagn.Microbiol.Infect.Dis.63, 330–333 (2009).
Caylan R., Kaklikkaya N., Aydin K.: An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital. J.Infect.Dis.57, 37–40 (2004).
Chiarini L., Bevivino A., Dalmastri C., Tabacchioni S., Visca P.: Burkholderia cepacia complex species: health hazards and biotechnological potential. Trends Microbiol.14, 277–286 (2006).
CLSI (Clinical and Laboratory Standards Institute): Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. Document M100-S18. Wayne (PA, USA) 2008.
Denton M., Kerr K.G.: Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin.Microbiol. Rev.11, 57–80 (1998).
De Oliveria Garcia D., Dall’agnol M., Rosales M., Azzuz Anac G.S., Alcantara N., Martinez M.B., Girón J.A.: Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell.Microbiol.5, 625–636 (2003).
Enoch D.A., Birkett C.I., Ludlam H.A.: Non-fermentative Gram-negative bacteria. Internat.J.Antimicrob.Agents.29(Suppl. 3), S33–S41 (2007).
Falagas M.E., Kastoris A.C., Vouloumanou E.K., Rafailidis P.I., Kapaskelis A.M., Dimopoulos G.: Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol.4, 1103–1109 (2009a).
Falagas M.E., Kastoris A.C., Voloumanou E.K., Dimopoulos G.: Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur.J.Clin.Microbiol.Infect.Dis.28, 719–730 (2009b).
Falagas M.E., Valkimadi P.E., Huang Y.T., Matthaiou D.K., Hsueh P.R.: Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J.Antimicrob.Chemother.62, 889–894 (2008).
Fouhy Y., Scanlon K., Schouest K., Spillane C., Crossman L., Avison M.B., Ryan R.P., Dow J.M.: Diffusible signal factor-dependent cell-cell signaling and virulence in the nosocomial pathogen Stenotrophomonas maltophilia. J.Bacteriol.189, 4964–4968 (2007).
Gales A.C., Jones R.N., Sader H.S.: Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY Antimicrobial Surveillance Programme (2001–2004). Clin.Microbiol. Infect.12, 315–321 (2006).
Gales A.C., Jones R.N., Sader H.S.: Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? J.Chemother.20, 38–42 (2008).
Garzia Paez J.I., Costa S.F.: Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J.Hosp.Infect.70, 101–108 (2008).
Garcia-Rodrigues J.A., Garcia Sanchez J.E., Garcia Garcia M.I., Garcia Sanchez E., Munoz Bellido J.L.: Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of β-lactam-β-lactamase inhibitor combinations. Diagn.Microbiol. Infect.Dis.14, 239–243 (1991).
Gilligan P.H., Lum G., Vandamme P.A.R., Whittier S.: Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea and Acidovorax, pp. 729–748 in P.R Murray (Ed.): Manual of Clinical Microbiology, 8th ed. ASM Press, Washington (DC) 2003.
Goss C.H., Otto K., Aitken M.L., Rubenfield G.D.: Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am.J.Resp.Crit.Care Med.166, 356–361 (2002).
Hejnar P., Kolar M., Chmela Z.: Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains. Folia Microbiol.49, 71–74 (2004).
Heylen K., Vanparys B., Peirsegaele F., Lebbe L., De Vos P.: Stenotrophomonas terrae sp.nov. and Stenotrophomonas humi sp.nov., two nitrate-reducing bacteria isolated from soil. Internat. J. Syst. Evol. Microbiol.57, 2056–2061 (2007).
Hoefe L.D., Monis D., Grooby W.L., Andrews S., Saint C.P.: Profiling bacterial survival through a water treatment process and subsequent distribution system. J.Appl.Microbiol.99, 175–186 (2005).
Insa R., Cecenado E., Goynes M.J., Bouza E.: In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J.Antimicrob.Chemother.59, 583–585 (2007).
Jones R.N., Sader H.S., Beach M.L.: Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains of non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001). Internat.J.Antimicrob.Agents22, 551–556 (2003).
Khan I., Mehta N.J.: Stenotrophomonas maltophilia endocarditis: a systemic review. Angiology53, 49–55 (2002).
Kudela V.: Prokaryot application in plant protection, pp. 189–190 in V. Kudela, A. Novacky, L. Fucikovsky: Plant Medical Bacteriology. (In Czech) Academia Press, Prague 2002.
Lai C.H., Chin W.W., Chin C., Huang C.K., Lin H.H., Chen W.F.: Central venous catheter-related Stenotrophomonas maltophilia bacteremia and associated relapsing bacteremia in hematology and oncology patients. Clin.Microbiol.Infect.12, 986–991 (2006).
Landman D., Gergescu C., Martin D.A., Quale J.: Polymyxins revisited. Clin.Microbiol.Rev.21, 449–465 (2008).
Leclercq R., Canton R., Giske C.: EUCAST Expert Rules in Antimicrobial Susceptibility Testing, ver. 1. European Society of Clinical Microbiology and Infectious Diseases; http://eucast.www137.server1.mensemedia.net/expert_rules/ (2008).
Libanore M., Bicocchi R., Pantaleoni M., Ghinelli F.: Community acquired infection due to Stenotrophomonas maltophilia: a rare cause of meningitis. Internat.J.Infect.Dis.8, 317–319 (2004).
Li X.Z., Mckay G.A., Poole K.: Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J.Antimicrob.Chemother.51, 803–811 (2003).
Looney W.J., Narifa M., Mühlemann K.: Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis.9, 312–323 (2009).
Miller S.I., Eenst R.K., Bader M.W.: LPS, TLR4 and infectious disease diversity. Nat.Rev.Microbiol.3, 36–46 (2005).
Minkwitz A., Berg A.: Comparison of antifungal activities and 16S ribosomal DNA sequences of clinical and environmental isolates of Stenotrophomonas maltophilia. J.Clin.Microbiol.39, 139–145 (2001).
Nicodemo A.C., Paez J.I.: Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur.J.Clin.Microbiol.Infect.Dis.26, 229–237 (2007).
Prince A.S.: Biofilms, antimicrobial resistance, and airway infection. N.Engl.J.Med.347, 1110–1111 (2002).
Sader H.S., Jones R.N.: Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Internat.J.Antimicrob. Agents25, 95–109 (2005).
Safdar A., Rorloston K.V.: Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin.Infect.Dis.45, 1602–1609 (2007).
Sanchez M.B., Hernandez A., Martinez J.L.: Stenotrophomonas maltophilia drug resistance. Future Microbiol.4, 655–660 (2009).
Sharma S., Chinyadza T., Chapnick E.K., Ghitan M.: Stenotrophomonas maltophilia infection during treatment for pancreatitis with imipenem/cilastatin. Clin.Microbiol.Newsletters30, 2 (2008).
Spencer R.C.: The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J.Hosp.Infect.30, 453–464 (1995).
Stürenburg E., Mack D.: Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J.Infect.47, 273–295 (2003).
Talmaciu I., Varlotta L., Mortensen J., Schidlow D.V.: Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatric Pulmonology30, 10–15 (2000).
Toleman M.A., Bennet P., Bennet M.D.C., Jones R., Walsh T.: Global emergence of trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg.Infect.Dis.13, 559–565 (2007).
Tsai S.H., Chao T.Y., Chou T.D., Dai M.S.: Stenotrophomonas maltophilia septicemia with pyomyositis in a chemotherapy-treated patient. Ann.Hematol.82, 452–454 (2003).
Waters V.J., Gomez M.I., Soong G., Amin S., Ernst R.K., Prince A.: Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect.Immun.75, 1698–1703 (2007).
Weber D.J., Rutala W.A., Sikbert-bennet E.E., Samsa G.P., Brown V., Niederman M.S.: Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect.Control.Hosp.Epidemiol.28, 825–831 (2007).
Wilkinson F.H., Kerr K.G.: Bottled water as a source of multi-resistant Stenotrophomonas and Pseudomonas species for neutropenic patients. Eur.J.Cancer Care7, 12–14 (1998).
Windhorst S., Frank E., Georgieva D.N.: The major extracellular protease of the nosocomial pathogen Stenotrophomonas maltophilia. J.Biol.Chem.277, 11042–11049 (2002).
Yemisen M., Mete B., Tunali Y., Yentur E., Ozturk R.: A meningitis case due to Stenotrophomonas maltophilia and review of the literature. Internat.J.Infect.Dis.12, 125–127 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nyč, O., Matějková, J. Stenotrophomonas maltophilia: Significant contemporary hospital pathogen — review. Folia Microbiol 55, 286–294 (2010). https://doi.org/10.1007/s12223-010-0043-4
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12223-010-0043-4